Live Breaking News & Updates on Roche Neuroimmunology|Page 1

Stay updated with breaking news from Roche neuroimmunology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Stanford University , United States , California Institute Of Technology , Los Angeles , Ellen Rose , Jennifer Zibuda , Hideki Garren , Roche Neuroimmunology , Novartis Pharma , Roche Ltd , University Of California , Head Of Communications , Investor Relations Communications , Roche Genentech Inc , Bayhill Therapeutics Inc , Prothena Corporation , Prothena Announces Appointment , Chief Medical , Gene Kinney , Chief Executive , Vice President , Global Head , Multiple Sclerosis , Neuromyelitis Optica Spectrum , Executive Director , Translational Medicine Expert ,

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Share:
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena s clinical pipeline.
Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company, said Gene Kinney, PhD, President and Chief Executive Officer. His experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for ....

Stanford University , United States , California Institute Of Technology , Los Angeles , Ellen Rose , Hideki Garren , Jennifer Zibuda , Roche Neuroimmunology , Novartis Pharma , University Of California , Roche Ltd , Head Of Communications , Investor Relations Communications , Roche Genentech Inc , Bayhill Therapeutics Inc , Prothena Corporation , Chief Medical , Gene Kinney , Chief Executive , Vice President , Global Head , Multiple Sclerosis , Neuromyelitis Optica Spectrum , Executive Director , Translational Medicine Expert , Executive Vice President ,